Based on typical breast cancer genomic markers (ER, PR, and HER2) and preliminary data from the ongoing Phase 1b/2 study in prostate cancer [31], the mechanism of action of SMK Therapy does not appear to be dependent on hormonal or HER2 status. The gene discussed is ERBB2; the disease is breast carcinoma.